Registered Members Login:
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

9 Pages (Click to Jump) V  « < 3 4 5 6 7 8 9 >   
Reply to this topic

post Posted: Sep 24 2007, 03:10 PM
  Quote Post

Posts: 8,001
Thanks: 403

In reply to: bloodclot on Wednesday 23/05/07 04:49pm

One for bottom-feeders which looks to be recovering, as predicted.

Well a few months on and a nice basing pattern has emerged,.... an ascending traingle with around $5.30 as res. Has pulled back to around the lower trend line tha past couple of sessions and have grabbed a few as a pre emptive strike at break of res(with tightish stop)
Although they may have to announce they are drilling for Iron or U308 to get it moving biggrin.gif
Suggested projected triangle target(if it can break) is around $6.


Chart as of 3:10
Attached image(s)
Attached Image



post Posted: Jun 2 2007, 02:01 AM
  Quote Post

Posts: 685
Thanks: 5

In reply to: bloodclot on Tuesday 29/05/07 07:55pm

Sorry bloodclot I did 70 Hrs and 65 hrs the last two weeks.But your right ,I know nothing of any upcoming events.Looks to be rebounding beautifly.I'm happy with this one. biggrin.gif

post Posted: May 29 2007, 07:55 PM
  Quote Post

Posts: 1,169
Thanks: 8

In reply to: bloodclot on Wednesday 23/05/07 03:49pm

Obviously no-one knows nothing - major brokers have been recommending to their clients - a no-brainer apparently.

post Posted: May 23 2007, 03:49 PM
  Quote Post

Posts: 1,169
Thanks: 8

One for bottom-feeders which looks to be recovering, as predicted.

Couldn't resist adding this one, even though it doesn't meet my normal investment criteria for a "blue chip" the speculative upside was too attractive.

Are there any RMD watchers out there who know if there are any upcoming events which will either reinforce or stymie the uptrend?

post Posted: Apr 25 2007, 04:34 PM
  Quote Post

Posts: 685
Thanks: 5

In reply to: kiril on Wednesday 25/04/07 08:23am

Could not agree more. Big one off charge covered in one quarter.Pretty impressed really.Bad part from supplier can happen to anyone.

post Posted: Apr 25 2007, 08:23 AM
  Quote Post

Posts: 881
Thanks: 253

Well Dan... Your chance to load up on these is upon us.

I think this will bounce shortly.....and we wont see this price again....EVER.


Share Cafe Sentifi Top themes and market attention on:

post Posted: Feb 5 2007, 06:04 PM
  Quote Post

Posts: 60
Thanks: 1

Second quarter results due out on Wednesday and it looks like the speculators are punting on some good numbers .
Of the non-resources stock RMD is still one of the stand out growth stocks on the market . Not getting too much attention while rescources run but one would expect it will attract some money when resources cool off .

post Posted: Jan 22 2007, 12:02 AM
  Quote Post

Posts: 685
Thanks: 5

In reply to: busylion on Sunday 14/01/07 10:15pm

I've been taking a few minutes to try comprehend all Farrell is saying there, the growth left in this stock is hugh,only, at present , 3 percent of the US market and 2 percent of rest of world market has been accessed for 10 years of 32 percent revenue growth.If what he is saying is correct, and he seems to have the runs on the board so to speak, I think I'll be taking every opportunity to load up. This may take alittle time to organise , so everyone please take your time ,there is no hurry.I can't get to coke a cola story out of my head after what Farrell is saying,what 40/50 years of continual growth and the best years to come,by my reading of it.25 years will make my retirement pleasureable.I hope he's right, and IMO no reason to doubt him.

post Posted: Jan 21 2007, 10:36 PM
  Quote Post

Posts: 685
Thanks: 5

In reply to: busylion on Sunday 14/01/07 10:15pm

Thanks for the info and your time in posting it, great read,got some of my super invested here.I'm thinking it can stay invested for some time yet.Thanks again.

post Posted: Jan 14 2007, 10:15 PM
  Quote Post

Posts: 208
Thanks: 2

Market awake to ResMed's value

ResMed is on top of the game as doctors finally come to grips with the severe consequences of sleep disorders writes Robert Gottliebsen

January 13, 2007
THE sleep disorder market is the biggest untapped medical market in the world.
It starts with snoring and sleep apnoea but it extends to heart attacks, diabetes, impotence, occupational health, obstetrics and many other areas.
Australian-based ResMed is the global leader in this market and is almost certainly one of Australia's premier growth stocks among the top 50 companies.

Only ABC Learning would rival it among the non-resource stocks.

ResMed is forecasting 20 per cent growth into the foreseeable future but it has been growing at an average annual rate of 32 per cent for 10 years.

The company's internal targets are closer to past performance.

Any company with turnover of around $1 billion growing at more than 20 per cent a year has a significant management challenge.

The market is backing ResMed management to deliver.

Excluding stock-based compensation, restructuring and acquisition expenses, the company earned $US1.42 a share in 2005-06 or $1.82 based on a US78c exchange rate.

Three years of 25 per cent growth would take earnings per share to about $3.50 and a 30 per cent growth rate would lift earnings to about $4.

That's why the stock is priced around $63 or a price-earnings ratio of 35.

If you use official US accounting standards, earnings per share fall to $US1.16 or $1.49, which takes the PE ratio above 40.

If anything goes wrong with a stock like ResMed over the next three years, the price will be severely punished.

ResMed and the US company Respironics each have about 40 per cent of the global sleep market. But ResMed has been growing its sleep business at twice the rate of the US company.

ResMed founding chairman and CEO Peter Farrell explains why the potential market for sleep disorder treatment is so huge.

He believes that about one in three or four people in the Western world have sleep disorders, of which the main disorder is obstructive sleep apnoea (OSA), which is the No1 cause of hypertension.

Hypertension is the main cause of two of the top three Western world killer illnesses - heart failure and stroke.

But it has also been discovered that sleep disorder problems exist in a large number of type 2 diabetes sufferers. Sleep disorders also play a role in obstetric and gynaecology problems.

Farrell says that although ResMed has achieved enormous growth rates, the potential is huge because the medical profession is only just waking up to the role of sleep disorders in so many of their patients' illnesses.

The sleep market starts with the "simple" problem of snoring.

Farrell says: "The problem is that if you are 'just a snorer', it is your bed partner that suffers and it probably breaks up more marriages than infidelity and financial issues.

"And we can fix it. Unfortunately, there is an appalling lack of education about sleep disordered breathing and obstructive sleep apnoea in medical schools.

"As a consequence, physicians often incorrectly refer patients with sleep disorders to urologists (study of urine), gastroenterologists (stomach), cardiologists (heart), neurologists (headaches), psychiatrists (personal), and so on, without any appreciation of the underlying sleep disorder pathology."

In addition, in the US the market for sleep disorder treatments is greatly slowed because a simple treatment process is made much more complex by elaborate testing bureaucracies.

Farrell says that apart from the lack of education in medical schools, one of the reasons the profession has been so slow to recognise the role of sleep disorders in so many killer illnesses is that "medicine stops when the lights go out".

"Think of a hospital," he says. "You've got the least qualified staff volunteering to work all night. And at night, there is the lowest number of staff to patients. The guy (just) sits there with a book."

A buzzer goes off. He goes down and fixes the drip. He goes back to the book. There is no observation.

"It is a bit like Sherlock Holmes to Doctor Watson," Farrell says. "Doctor Watson, you see but you don't observe. There is no observation at night.

"It is all 'I'll see you in the morning'."

ResMed is working to change medical attitudes, but it is a slow process.

It has about 4 million patients being treated around the world and it sells about 80,000 breathing devices and 360,000 masks each month.

The devices vary from a standard $1000 unit to sophisticated ventilators that closely measure breathing for patients with severe heart problems. Margins on the standard lower-priced units are low, but are much higher once more sophisticated equipment is used.

Most patients need new masks regularly, so the company has a substantial annuity income and the mask business is high-margin.

And because the cause of people's illness is being curbed, their lives are being extended and so the ResMed annuity stream is a long-term one.

If there is a big rise in the usage of sleep disorder treatments, then not only will ResMed enjoy initial income from the sale of devices but its annuity stream will underwrite a higher level of long-term earnings.

And to further assist annuity streams, many of the new ResMed masks actually trigger a re-ordering process once they are near the end of their life.

ResMed is working in the US to simplify its apparatus and therefore widen the market.

It has been helped by the US private trucking giant Schneider, which has about 15,000 drivers.

Chief executive Chris Lofgren went on a ResMed machine and saw the benefits. Now 1000 of his truck drivers have had their sleep disorders eliminated by ResMed machines. Lofgren has told them: "If you don't use your machine, go find another job."

Penetrating the US occupational health and safety market will be a long process, but the Schneider policy was a big breakthrough and if, longer-term, Schneider health problems are substantially reduced, it will help open the US market.

What can go wrong with ResMed? Obviously, the current dramatic results linking sleep disorders to so many killer illnesses must not be contradicted by later findings and the high machine safety record must be maintained.

It is remarkable that so few companies compete in this market.

To protect its market leadership, ResMed has 1000 patents existing or in progress and has effectively established a spider web of patents so that if a patent is about to expire, the company has intellectual property process to follow through.

The company believes this protects its position, but obviously if a new sleep disorder treatment breakthrough was made by a rival it would affect its growth, although big new developments usually take time.

ResMed spends about 6 per cent of its revenue on research and has a strong pipeline of new products to improve sleep treatments and develop new markets.

The pains of growth won't be easy to manage. The company recently spent $250 million building a factory in Sydney and now thinks it probably should have spent four times that, given the growth rate.

Because of the growth rate required by the market, management succession will be important.

It is likely that in the next year or two Farrell will hand over the CEO reins to his No2, Kieran Gallahue, but he will remain as founding chairman.

Two years ago Gallahue was promoted to president of ResMed Global, assuming responsibility for global operations, new business development and product innovation, in preparation for a future CEO handover.


9 Pages (Click to Jump) V  « < 3 4 5 6 7 8 9 >

Back To Top Of Page
Reply to this topic

You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.